Delivery Order SPE2DB24D2100-SPE2DB25FBFLK
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order for Copaxone 40 mg/ml syringes valued at $1,041.36 by the Defense Logistics Agency's Medical Supply Chain on August 19, 2025. This competitive, firm fixed-price contract has an ultimate completion date of August 20, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which is valued at $999,999,999 and extends through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,989.35 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for July 22, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of pharmaceutical procurement through the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a $4,368 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Copaxone 40 mg/ml syringes. The contract, awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken,...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of COPAXONE 40 MG/ML SYRINGE. The $1,055.54 delivery order, which does not have a set-aside designation, has a completion date of February 7, 2024. AmerisourceBergen Drug Corp is also the prime contractor on a larger indefinite delivery contract (IDC) awarded by DLA with a...
- The Defense Logistics Agency has awarded a firm fixed price delivery order contract worth $1,069.46 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of COPAXONE 40 MG/ML syringes. The contract has a completion date of February 16, 2024. Amerisourcebergen Drug Corp is a prime contractor that provides a wide range of pharmaceutical products and medical supplies to U.S. government agencies, including the Department of Defense. This delivery order...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was made by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,846.69 firm fixed-price delivery order is for the supply of Copaxone 40 mg/mL syringes, with an ultimate completion date of October 17, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of COPAXONE 40 MG/ML SYRINGEML. The contract has a ceiling value of $1,583.28 and an ultimate completion date of September 25, 2024. The contract is a firm fixed price delivery order and is not set aside for any preference program. This award is likely part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- The Defense Logistics Agency Troop Support Medical awarded a $6,026.32 firm fixed price delivery order to Amerisourcebergen Drug Corporation for COPAXONE 20 MG/ML SYRINGEML. The place of performance is Conshohocken, Pennsylvania. The period of performance is from August 16, 2023 through August 17, 2023. This delivery order was awarded under an indefinite-delivery/indefinite-quantity contract vehicle to supply pharmaceutical products in support of the Defense Logistics Agency's medical supply...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The award is for the provision of Copaxone 40 mg/ml syringes, a specialty pharmaceutical product. The delivery order has a ceiling value of $1,583.28 and a performance period through March 29, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA Troop Support Medical, valued...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order valued at approximately $6,037 by the Defense Logistics Agency Troop Support Medical to provide Copaxone 40 mg/ml syringes. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is August 15, 2023 through August 16, 2023. No subcontractors or set aside designations were indicated. This delivery...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFLKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,580.20 to AmerisourceBergen Drug Corp for the supply of Copaxone 40 mg/ml syringes. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, utilizes firm fixed price terms and was competitively awarded without set-aside provisions. AmerisourceBergen's Corporate Office, located in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Copaxone, an injectable medication used primarily for treating multiple sclerosis, represents one component of the extensive therapeutic categories covered under this prime vendor agreement, which serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 7/25/25 |